-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $156

Benzinga·10/15/2026 14:04:30
Listen to the news
Stifel analyst James Condulis maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $136 to $156.